Atrovent Related Published Studies
Well-designed clinical trials related to Atrovent (Ipratropium)
Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. [2009.08]
Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia. [2008.03]
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. [2007.06]
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. [2007.03.06]
Efficacy and tolerance of high-dose inhaled ipratropium bromide vs. terbutaline in intubated premature human neonates. [2007]
Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. [2006.11]
A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. [2006.11]
Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan. [2006.09]
Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. [2006.05]
Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. [2006.04]
Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects. [2006.04]
Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients? [2006]
Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease. [2006]
The effect of ipratropium nasal spray on bronchial methacholine challenge. [2005.09]
Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. [2005.07]
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. [2005.05]
The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm. [2005.03]
Ipratropium bromide HFA. [2005]
Well-designed clinical trials possibly related to Atrovent (Ipratropium)
High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. [2009.08]
UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 359(15):1543-1554. [2009.03]
Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. [2009.03]
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. [2009.02.19]
A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. [2009]
A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. [2008.12]
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. [2008.09.24]
Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma. [2008.06]
Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma. [2008.06]
Bronchodilator responsiveness in patients with COPD. [2008.04]
Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. [2008.04]
Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. [2008]
Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. [2008]
Effects of short-acting bronchodilators added to maintenance tiotropium therapy. [2007.11]
Short-acting bronchodilators added to maintenance tiotropium therapy. [2007.09.21]
Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. [2007.09]
Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. [2007.06]
Pharmacological modulation of gut mucosal and large vessel blood flow. [2007.03.15]
Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. [2006.10]
An oral selective M3 cholinergic receptor antagonist in COPD. [2006.10]
[Effect of intravenous magnesium sulfate on chronic obstructive pulmonary disease exacerbations requiring hospitalization: a randomized placebo-controlled trial] [2006.08]
Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. [2006.08]
Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. [2006.07]
[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities] [2006.06]
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. [2006.06]
Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. [2006.04]
Different bronchodilator combinations have similar effects on health status in COPD. [2006]
Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. [2005.12.15]
[Clinical and functional benefits of adding theophylline to a standard treatment with short acting bronchodilators in patients with COPD] [2005.10]
Effects of two nebulization regimens on heart rate variability during acute asthma exacerbations in children. [2005.05]
Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD. [2005.04]
Bronchodilators in bronchoscopy-induced airflow limitation in allergen-sensitized cats. [2005.03]
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. [2005.02.15]
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. [2005.01]
Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. [2005]
Other research related to Atrovent (Ipratropium)
Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. [2009.09.06]
Functional response to inhaled salbutamol and/or ipratropium bromide in Ascaris suum-sensitised cats with allergen-induced bronchospasms. [2009.08.19]
Comparative efficacy of combined nebulized salbutamol with ipratropium bromide and nebulized adrenaline to treat children with acute bronchiolitis. [2009.07]
Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. [2009.06]
A pilot study comparing the antispasmodic effects of inhaled salmeterol, salbutamol and ipratropium bromide using different aerosol devices on muscarinic bronchoconstriction in healthy cats. [2009.05]
Efficacy and safety of intranasal xylometazoline and ipratropium in patients with common cold. [2009.04]
Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI *. [2009.03]
[Association of A/T polymorphism of the CHRM2 gene with bronchodilator response to ipratropium bromide in asthmatic children] [2009]
Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. [2008.12]
A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease. [2008.08]
Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults. [2008.08]
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. [2008.08]
Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. [2008.08]
Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. [2008.06]
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: Response by beta-agonist reversibility. [2008.05.01]
Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. [2008.03.05]
[Efficacy of pulmicort suspension plus salbutamol and ipratropium bromide for management of acute asthma exacerbation in children: a comparative study.] [2008.03]
Pharmacological mydriasis secondary to ipratropium bromide: a cause of unilateral dilated pupil. [2008.03]
A randomized study of tiotropium Respimat((R)) Soft Mist(TM) Inhaler vs. ipratropium pMDI in COPD. [2008.01]
Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD. [2008]
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: Response by beta-agonist reversibility. [2008]
Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. [2008]
Efficacy of salbutamol and ipratropium bromide in the management of acute bronchiolitis--a clinical trial. [2008]
[Voiding difficulties in a child attributed to the use of ipratropium and salbutamol] [2007.12.08]
Efficacy of Salbutamol and Ipratropium Bromide in the Management of Acute Bronchiolitis - A Clinical Trial. [2007.11.28]
Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. [2007.11.15]
Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD. [2007.10.16]
Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol. [2007.10]
Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. [2007.09.17]
Exploratory economic evaluation of patients with COPD on a combination product versus individual components (ipratropium bromide and albuterol). [2007.07]
Effect of interactive ternary mixtures on dispersion characteristics of ipratropium bromide in dry powder inhaler formulations. [2007.04.20]
New ipratropium formulation to decrease nebulization time. [2007.02]
Efficacy and safety of topical combinations of ipratropium and xylometazoline for the treatment of symptoms of runny nose and nasal congestion associated with acute upper respiratory tract infection. [2007.01]
Physicochemical compatibility of fluticasone-17- propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions. [2007]
Same efficacies of ipratropium and salbutamol in reversing methacholine-induced bronchoconstriction. [2006.11]
Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. [2006.07.19]
[Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease] [2006.06]
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. [2006.04.19]
Manufacture, characterization, and pharmacodynamic evaluation of engineered ipratropium bromide particles. [2006]
The efficacy of nebulized albuterol/ipratropium bromide versus albuterol alone in the prehospital treatment of suspected reactive airways disease. [2005.10]
Airway tone during exercise in healthy subjects: effects of salbutamol and ipratropium bromide. [2005.06]
[Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol] [2005.05]
Protective effect of ipratropium bromide on bronchoconstriction induced by sulfur dioxide exposure during apricot sufurization processes that causes asthma-like syndrome in agricultural environment. [2005.05]
Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. [2005.04.15]
A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. [2005.03]
Effect of ipratropium bromide on EIB in children depends on vagal activity. [2005.03]
A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma. [2005.02]
Use of 0.06% ipratropium bromide nasal spray in children aged 2 to 5 years with rhinorrhea due to a common cold or allergies. [2005.01]
|
